BioNTech SE
98.13USD
-0.5300 (-0.54%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.76▲ | $0.66 | 3 | 0 |
| Next quarter | $-0.75▲ | $-0.84 | 2 | 1 |
| Current year | $-4.63▼ | $-4.58 | 1 | 6 |
| Next year | $-4.9▼ | $-4.49 | 2 | 4 |
Beat in 0 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-2.08 | $-2.22 | -0.14 (-6.8%) |
| 2026-03-31 | $-1.92 | $-1.95 | -0.03 (-1.6%) |
| 2025-12-31 | $-0.25 | $-0.33 | -0.08 (-30.4%) |
| 2025-09-30 | $0.1 | $-0.12 | -0.22 (-220.3%) |
208 ratings from 23 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| BMO Capital | Downgraded from Outperform | Market Perform | $128 $105 | Sep 8, 2026 |
| Canaccord Genuity | Maintained | Buy | $142 $136 | Aug 31, 2026 |
| Citigroup | Maintained | Buy | $130 $125 | Aug 5, 2026 |
| Evercore ISI Group | Maintained | Outperform | $135 $130 | Aug 5, 2026 |
| Morgan Stanley | Maintained | Overweight | $126 $119 | Jul 8, 2026 |
| UBS | Upgraded from Neutral | Buy | $117 $135 | May 27, 2026 |
| Bernstein | Initiated | Market Perform | $96 | May 22, 2026 |
| Canaccord Genuity | Maintained | Buy | $171 $158 | May 6, 2026 |
| Wells Fargo | Maintained | Overweight | $150 $140 | May 6, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $130 | Apr 27, 2026 |
| Morgan Stanley | Maintained | Overweight | $125 $126 | Apr 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $140 $130 | Mar 31, 2026 |
| Morgan Stanley | Maintained | Overweight | $134 $125 | Mar 11, 2026 |
| Canaccord Genuity | Maintained | Buy | $171 | Mar 11, 2026 |
| Citigroup | Maintained | Buy | $145 $130 | Mar 11, 2026 |
| TD Cowen | Maintained | Hold | $116 $94 | Mar 11, 2026 |
| BMO Capital | Maintained | Outperform | $143 $128 | Mar 11, 2026 |
| Jefferies | Maintained | Buy | $151 $138 | Mar 10, 2026 |
| Goldman Sachs | Upgraded from Neutral | Buy | $115 $142 | Jan 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $136 $140 | Nov 10, 2025 |
| UBS | Maintained | Neutral | $115 $117 | Nov 6, 2025 |
| JP Morgan | Maintained | Neutral | $121 $120 | Oct 23, 2025 |
| Morgan Stanley | Maintained | Overweight | $133 $131 | Oct 10, 2025 |
| JP Morgan | Maintained | Neutral | $116 $121 | Sep 22, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $136 | Sep 8, 2025 |
5 filings from 2 insiders · 0 buy / 0 sell over 6m
Officers and directors of BNTX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sahin UgurOfficer, Chief Executive Officer; 10% owner | Sell | 36.0k | $97.78 | $3.52M | Sep 9, 2026 |
| Sahin UgurOfficer, Chief Executive Officer; 10% owner | Sell | 37.0k | $99.20 | $3.67M | Sep 8, 2026 |
| Sahin UgurOfficer, Chief Executive Officer; 10% owner | Sell | 31.5k | $103.52 | $3.26M | Sep 4, 2026 |
| Sahin UgurOfficer, Chief Executive Officer; 10% owner | Sell | 45.0k | $102.85 | $4.63M | Sep 3, 2026 |
| POETTING SIERKChief Operating Officer | Sellindirect | 50.0k | $110.56 | $5.53M | Apr 22, 2026 |
No analyst notes on BNTX yet.
Analyst Ratings
20 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 13 | 5 | 0 | 1 | Buy2.35 |
| 1 mo ago | 1 | 14 | 4 | 0 | 1 | Buy2.30 |
| 2 mo ago | 1 | 14 | 5 | 0 | 0 | Buy2.20 |
| 3 mo ago | 1 | 14 | 5 | 0 | 0 | Buy2.20 |